2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157928
    Keap1-Nrf2-IN-18 98%
    Keap1-Nrf2-IN-18 (Compound 22) is an orally active Keap1-Nrf2 protein-protein interaction (PPI) inhibitor with good pharmacokinetics (PK) profiles and more potent in vivo activities in rats. Keap1-Nrf2-IN-18 has the strongest inhibitory activity in structure−activity relationship (SAR) study (KD = 0.0029 μM).
    Keap1-Nrf2-IN-18
  • HY-157929
    Keap1-Nrf2-IN-19 98%
    Keap1-Nrf2-IN-19 (compound 33) is an oral active Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with the Kd value of 0.0014 μM. Keap1-Nrf2-IN-19 exhibits less than 50% inhibition at 30 μM against hERG and 10 μM against CYPs.
    Keap1-Nrf2-IN-19
  • HY-157963
    RIPK1-IN-23 3031534-16-1 98%
    RIPK1-IN-23 (compound 19) is a RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities.
    RIPK1-IN-23
  • HY-157992
    LM-021 1022282-98-9 98.27%
    LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research.
    LM-021
  • HY-157995
    Dyrk1A-IN-7 98%
    Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases.
    Dyrk1A-IN-7
  • HY-158022
    CTSL/CAPN1-IN-1 98%
    CTSL/CAPN1-IN-1 (compound 14a) is an oral active CTSL and CAPN1 inhibitor with the IC50  values of 3.34 nM and 375.1 nM for CTSL and CAPN1, respectively. CTSL/CAPN1-IN-1 shows anticoronaviral activity and anti-inflammatory effect.
    CTSL/CAPN1-IN-1
  • HY-158036
    PROTAC STING Degrader-2 3023095-61-3 98%
    PROTAC STING degrader-2 is a protein Degrader that targets Stimulator of interferon genes (STING) (DC50=0.53 μM). PROTAC STING Degrader-2 is combined with STING protein and E3 ubiquitin ligase in a covalent manner to induce the degradation of STING protein. PROTAC STING Degrader-2 can be used to investigate the role of STING in autoinflammation and autoimmune diseases (PINK: STING binder (HY-145009); Blue: VHL ligand (HY-164043); Black: linker).
    PROTAC STING Degrader-2
  • HY-158048
    UNC9036 98%
    UNC9036 is a PROTAC-based STING degrader, with a DC50 of 227 nM. UNC9036-mediated STING degradation is proteasome and VHL dependent (Structure Note: Red, STING agonist diABZI (HY-112921A); Blue, VHL ligand VH032 (HY-120217); Black, linker).
    UNC9036
  • HY-158058
    WYJ-2 3029403-05-9 98%
    WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC).
    WYJ-2
  • HY-158093
    NIC-12 2409826-23-7 98%
    NIC-12 is a potent NLRP3 inhibitor. NIC-12 selectively reduces circulating IL-1ß levels in the LPS-endotoxemia mice model. NIC-12 inhibits NLRP3 inflammasome activation in mouse macrophages.
    NIC-12
  • HY-158111
    NLRP3-IN-34 1392502-55-4 98%
    NLRP3-IN-34 (Compound T10) is an inhibitor for NLRP3 inflammasome. NLRP3-IN-34 inhibits ROS production, NLRP3 inflammasome-dependent IL-1β production (IC50 is 0.48 μM in cells J774A.1), and inhibits pyroptosis. NLRP3-IN-34 exhibits anti-inflammatory activity against DSS-induced peritonitis.
    NLRP3-IN-34
  • HY-158120
    LasR agonist 1 98%
    LasR agonist 1 (9) is a LasR agonist, with an EC50 of 0.7 μM. Used for P. aeruginosa research.
    LasR agonist 1
  • HY-158148
    CSF1R-IN-23 2935480-17-2 98%
    CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC50 of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable.
    CSF1R-IN-23
  • HY-158159
    IL17A-IN-1 98%
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer.
    IL17A-IN-1
  • HY-158163
    Herbicidal agent 4 98%
    Herbicidal agent 4 (compound V-2) is an auxinic herbicidal agent. Herbicidal agent 4 may also be an immune activator while upregulating the defense genes and increasing content of jasmonic acid.
    Herbicidal agent 4
  • HY-158166
    DNA-PK-IN-13 3036751-03-5 98%
    DNA-PK-IN-13 (Compound SK10) is a DNA-PK inhibitor that exhibits potent inhibitory activity (IC50= 0.11 nM). DNA-PK-IN-13 regulates tumor cell proliferation by decreasing the expression level of γH2A.X and enhancing the sensitivity of tumor cells to chemotherapeutic agents. DNA-PK-IN-13 is suitable for oncology studies.
    DNA-PK-IN-13
  • HY-158167
    AhR agonist 5 98%
    AhR agonist 5 is an AHR agonist (EC50 = 6 nM). From patent WO2024061187A1, compound 5.
    AhR agonist 5
  • HY-158168
    AhR agonist 6 3033281-96-5 98%
    AhR agonist 6 (Compound 6) is an agonist for aryl hydrocarbon receptor (AhR), with an EC50 of 0.01 nM.
    AhR agonist 6
  • HY-158169
    AhR agonist 7 3033281-98-7 98%
    AhR agonist 7 (Compound 8) has a good activation activity against AhR (ECsub>50 = 13nM).
    AhR agonist 7
  • HY-158171
    Cbl-b-IN-17 98%
    Cbl-b-IN-17 (Example-40) is an inhibitor of Cbl-b with an IC50 value <100 nM.
    Cbl-b-IN-17
Cat. No. Product Name / Synonyms Application Reactivity